- Home
- GHI vs YARW Comparison
GHI vs YARW Comparison
Compare GHI & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | YARW |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 114.6M |
| IPO Year | 1998 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GHI | YARW |
|---|---|---|
| Price | $6.31 | $29.30 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 58.8K | 31.1K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | ★ 22.93% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,389,766.00 | N/A |
| Revenue This Year | $273.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.71 | $27.31 |
| 52 Week High | $10.94 | $44.28 |
Technical Indicators
Market Signals| Indicator | GHI | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 34.88 |
| Support Level | $6.01 | $27.31 |
| Resistance Level | $6.76 | $43.96 |
| Average True Range (ATR) | 0.20 | 3.53 |
| MACD | -0.04 | -1.19 |
| Stochastic Oscillator | 25.68 | 7.92 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.